- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07481500
Spekulumfri intravitreal injektion med retraktion ved hjælp af vatpind: En randomiseret undersøgelse af smerte, proceduretid, patienttilfredshed og sikkerhed (IVI-RETRACT)
Speculum-fri intravitreal injektion ved brug af vatpindstræk: En randomiseret kontrolleret undersøgelse, der sammenligner smerteopfattelse, procedurevarighed, patienttilfredshed og sikkerhed mellem øjenlågsspeculum- og vatpindstrækteknikker
This randomized controlled trial compares two techniques for eyelid retraction during intravitreal injection (IVI): an adjustable solid-blade eyelid speculum (Group A) and single-hand retraction of the upper eyelid with one cotton-tipped applicator (Group B), in patients with neovascular age-related macular degeneration (including polypoidal choroidal vasculopathy), diabetic macular edema, or retinal vein occlusion treated at Walailak University Hospital, Nakhon Si Thammarat, Thailand.
The study evaluates four outcomes: (1) pain on a 0-10 numbered pain scale with a faces pictogram, 1-5 minutes after injection; (2) procedure duration from the first contact of the retraction device with the eyelid to its removal; (3) patient satisfaction on a 5-item Likert questionnaire; and (4) safety, including subconjunctival hemorrhage, corneal abrasion, lens touch, vitreous hemorrhage, endophthalmitis, retinal detachment, and intraocular pressure elevation.
In both groups, the cap of the insulin syringe is used as an injection-site marker instead of a caliper. Randomization was stratified by diagnosis and prior injection history using permuted blocks of 4 and 6. All 129 participants were randomized and injected on September 9, 2026.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Background:
Intravitreal injection is one of the most frequently performed ophthalmic procedures. Eyelid specula are widely used to keep the eye open but may cause discomfort. Cotton-tipped applicator retraction is an alternative that may reduce pain, and when a single applicator is held in one hand, the other hand remains free for injection-site marking and injection, so that one surgeon can complete the procedure without an assistant. Randomized data on procedure duration and satisfaction are limited.
Study Design:
Single-center, prospective, parallel-group randomized controlled trial with 1:1 allocation to an eyelid speculum (Group A) or cotton-tipped applicator retraction (Group B). The principal investigator generated stratified permuted-block sequences (block sizes 4 and 6) with Study Randomizer software; there were six strata: diagnosis (nAMD / DME / RVO) x prior injection history (injection-naive / previously injected). A research assistant placed the assignments in sequentially numbered, opaque, sealed envelopes, which another research assistant opened immediately before each procedure.
Interventions:
One vitreoretinal surgeon performed all injections without an assistant. Injections were given in the superotemporal quadrant in right eyes and the superonasal quadrant in left eyes (surgeon preference, same in both groups). All participants received tetracaine 0.5% and povidone-iodine 5% drops in the waiting area (contact time of at least 5 minutes), povidone-iodine 10% periocular skin preparation, a second instillation of tetracaine, and a fenestrated cloth drape. Anti-VEGF agents (bevacizumab, aflibercept, or faricimab) were prepared by the hospital pharmacy in 1-mL insulin syringes with a fixed 31G needle (Terumo). Group A: adjustable solid-blade eyelid speculum with a screw lock (PMS) retracting the upper and lower eyelids. Group B: one sterile cotton-tipped applicator held in the left hand to retract the upper eyelid; conversion to the speculum if retraction failed after 2 attempts. If the first attempt failed because of forceful eyelid squeezing or a marked Bell phenomenon, the participant was asked to close the eye, the applicator was used to retract the lower eyelid, and the injection was given in the inferotemporal or inferonasal quadrant. The injection site was marked with the povidone-iodine-dipped cap of the insulin syringe. Levofloxacin 0.5% was instilled after injection.
Outcome Measures:
All four outcomes are primary. Pain (0-10 numbered pain scale with faces), procedure duration (seconds), and satisfaction (5-item Likert questionnaire, total 5-25) were assessed on Day 0, 1-5 minutes after injection. Safety outcomes were assessed on Day 0, Day 1 (telephone), and Week 4 (clinic visit). Pain, procedure duration, and satisfaction are tested at a Bonferroni-adjusted alpha of 0.0167; safety is summarized descriptively (statistical analysis plan version 1.0, locked September 21, 2026).
Masking:
Open label. Participants, the surgeon, and the research assistants who timed the procedure and assessed the outcomes were aware of group assignment.
Sample Size:
Based on Chen et al. (2025) (pooled SD 1.71 for pain; Cohen's d = 0.57), with alpha = 0.025 (Bonferroni correction for 2 outcomes) and 80% power, 60 patients per group are required for pain (the earlier version of this record reported 52 per group because of a calculation error) and 46 per group for procedure duration. The enrollment target was 60 per group (120 total). All eligible patients who attended the injection session and gave consent were randomized (actual enrollment, 129).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Changwat Nakhon Si Thammarat
-
Tha Sala, Changwat Nakhon Si Thammarat, Thailand, 80160
- Walailak University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Diagnosed with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or retinal vein occlusion (RVO)
- Scheduled for intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab)
- Able to provide written informed consent
Exclusion Criteria:
- Active ocular infection or inflammation
- Known allergy to povidone-iodine, tetracaine, or levofloxacin
- Inability to cooperate with the injection procedure
- Concurrent participation in another interventional clinical trial
- Anatomical eyelid abnormality precluding use of either retraction technique
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Eyelid Speculum (Group A)
Intravitreal injection performed with an adjustable solid-blade eyelid speculum with a screw lock (PMS) retracting the upper and lower eyelids. The speculum is inserted immediately before injection-site marking and injection and removed immediately after needle withdrawal. |
An adjustable solid-blade eyelid speculum with a screw lock (PMS) is inserted to retract the upper and lower eyelids before intravitreal injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). The speculum is removed immediately after needle withdrawal. |
|
Eksperimentel: Cotton-Tipped Applicator (Group B)
A single sterile cotton-tipped applicator, held in the surgeon's left hand, retracts the upper eyelid (speculum-free) before intravitreal injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). If the first attempt fails because of forceful eyelid squeezing or a marked Bell phenomenon, the participant is asked to close the eye, the applicator is used to retract the lower eyelid, and the injection is given in the inferotemporal or inferonasal quadrant. The eyelid speculum is used if retraction fails after 2 attempts. The applicator is removed immediately after needle withdrawal. |
One sterile cotton-tipped applicator, held in the surgeon's left hand, is used to retract the upper eyelid (speculum-free) before intravitreal anti-VEGF injection (bevacizumab, aflibercept, or faricimab) with a Terumo 31G insulin syringe in the superotemporal quadrant in right eyes or the superonasal quadrant in left eyes (surgeon preference, same in both groups). The right hand marks the injection site and injects. If the first attempt fails because of forceful eyelid squeezing or a marked Bell phenomenon, the participant is asked to close the eye, the applicator is used to retract the lower eyelid, and the injection is given in the inferotemporal or inferonasal quadrant. The eyelid speculum is used if retraction fails after 2 attempts. The applicator is removed immediately after needle withdrawal. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pain Perception
Tidsramme: 1-5 minutes after intravitreal injection (Day 0)
|
Patient-reported pain score on a 0-10 numbered pain scale with a faces pictogram and verbal categories (0 = no pain; 10 = worst pain). The participant pointed to or stated a level, and a research assistant recorded the score after the participant had left the injection room. |
1-5 minutes after intravitreal injection (Day 0)
|
|
Procedure Duration
Tidsramme: During intravitreal injection procedure (Day 0)
|
Time in seconds from the first contact of the retraction device (speculum or cotton-tipped applicator) with the eyelid to its complete removal after needle withdrawal, measured by a research assistant with a stopwatch. |
During intravitreal injection procedure (Day 0)
|
|
Patient Satisfaction
Tidsramme: 1-5 minutes after intravitreal injection (Day 0)
|
Total score on a 5-item Likert satisfaction questionnaire in Thai (item 3, squeezing or pressure on the eyelid, reverse-scored; total 5-25; higher scores indicate greater satisfaction), administered at the same assessment as the pain score. |
1-5 minutes after intravitreal injection (Day 0)
|
|
Procedure-Related Complications
Tidsramme: Day 0, Day 1, and Week 4 post-injection
|
Incidence of ocular complications, including subconjunctival hemorrhage, corneal abrasion, lens touch, vitreous hemorrhage, endophthalmitis, rhegmatogenous retinal detachment, and intraocular pressure greater than 25 mmHg, assessed on Day 0 (clinic), Day 1 (telephone call), and Week 4 (clinic visit). |
Day 0, Day 1, and Week 4 post-injection
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jakkrit Juhong, MD, Walailak University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Øjensygdomme
- Embolisme og trombose
- Uveal Sygdomme
- Nethindesygdomme
- Choroid sygdomme
- Metaplasi
- Venøs trombose
- Trombose
- Choroidal neovaskularisering
- Neovaskularisering, patologisk
- Patologiske tilstande, tegn og symptomer
- Opførsel
- Behandlingsoverholdelse og compliance
- Sundhedsadfærd
- Polypoid choroidal vaskulopati
- Retinal veneokklusion
- Patienttilfredshed
Andre undersøgelses-id-numre
- WURCT5954
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
De-identified individual participant data underlying the results reported in the article (baseline characteristics, pain, procedure duration, satisfaction, and adverse events), with a data dictionary, will be shared on reasonable request to the principal investigator.
IPD-delingstidsramme
Beginning after publication of the primary results and for at least 5 years thereafter.
IPD-delingsadgangskriterier
Qualified researchers who submit a methodologically sound proposal to the principal investigator (jakkrit.ju@wu.ac.th). Data will be shared after approval of the proposal and signature of a data use agreement, in accordance with the requirements of the Ethics Committee in Human Research, Walailak University.
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .